KRAS mutations, which are present in approximately 40% of CRC cases, determine constitutive activation of RAS, and promote tumorigenesis as well as modulation of the tumor microenvironment by inducing immune escape and cancer progression [88], reason why RAS mutations are generally associated with poor prognosis and low response to conventional CRC therapies [89]. This evidence concerns the gene KRAS and cancer.